We are monitoring the impact of COVID-19 & Recession alarm on APAC Ophthalmology Therapeutics Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Ophthalmology Therapeutics Market Research Report – Segmented By Indication, End User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2022 to 2027)

Published: January, 2022
ID: 1046
Pages: 145

APAC Ophthalmology Therapeutics Market Size (2022 to 2027)

The Ophthalmology Therapeutics Market in APAC was worth USD 5.31 billion in 2022 and is estimated to grow at a CAGR of 8.5%, to reach USD 7.98 billion by 2027.

Ophthalmology is the branch of medicine that deals with the eye's anatomy, physiology, and diseases. Recent advancements in genetics and stem cell biology have brought several changes to the Ophthalmology Therapeutics Market.

The growing prevalence of vision impairment drives Asia Pacific Ophthalmology Therapeutics. According to a recent update by WHO, the prevalence of visual impairment is nearly 285 million globally. Of these, 246 million people have moderate to severe visual impairment. South-East Asia and the Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of the market include increasing awareness about the importance of detecting ophthalmic diseases as early as possible and efficient diagnostic tools.

However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the market.

This research report on the Asia Pacific Ophthalmology Therapeutics Market has been segmented and sub-segmented Market into the following categories:

By Indication: 

  • Glaucoma
  • Dry Eye Syndrome
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Age-related Macular Degeneration
  • Macular Edema
  • Allergic Conjunctivitis

By End User: 

  • Hospitals
  • Eye Clinics
  • Diagnostic Centres
  • Patients

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, Asia-Pacific is the fastest-growing region with a CAGR of xx% during the forecast period. Within Asia-Pacific, Japan is the largest market for Opthalmology therapeutics accounting for a share of approximately 45%, followed by China. Glaucoma is the largest indication segment accounting for a share of approximately XX%.

Prominent companies in the APAC Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis         

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Allergan, Inc.                              

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck & Co Inc                         

                9.3 Pfizer                            

                9.4 Roche                           

                9.5 Novartis (Alcon)                       

                9.6 Valeant                        

                9.7 Regeneron                 

                9.8 Santen                         

                9.9 Bayer                            

                9.10 Senju                          

                9.11 Lpath                          

                9.12 Eye Gate Pharmaceuticals                 

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Asia-Pacific Ophthalmology Therapeutics Market, By Region, From 2022 - 2027 (USD Billion)
  2. Asia-Pacific Ophthalmology Therapeutics Market, By Indication, From 2022 - 2027 (USD Billion)
  3. Asia-Pacific Glaucoma Market, By Region, From 2022 - 2027 (USD Billion)
  4. Asia-Pacific Dry Eye Syndrome Market, By Region, From 2022 - 2027 (USD Billion)
  5. Asia-Pacific Diabetic Retinopathy Market, By Region, From 2022 - 2027 (USD Billion)
  6. Asia-Pacific Retinal Vein Occlusion Market, By Region, From 2022 - 2027 (USD Billion)
  7. Asia-Pacific Age-Related Macular Degeneration (AMD) Market, By Region, From 2022 - 2027 (USD Billion)
  8. Asia-Pacific Macular Edema Market, By Region, From 2022 - 2027 (USD Billion)
  9. Asia-Pacific Allergic Conjunctivitis Market, By Region, From 2022 - 2027 (USD Billion)
  10. Asia-Pacific Ophthalmology Therapeutics Market, By End-User, From 2022 - 2027 (USD Billion)
  11. Asia-Pacific Hospitals Market, By Region, From 2022 - 2027 (USD Billion)
  12. Asia-Pacific Eye Clinics Market, By Region, From 2022 - 2027 (USD Billion)
  13. Asia-Pacific Diagnostic Centers Market, By Region, From 2022 - 2027 (USD Billion)
  14. Asia-Pacific Patients Market, By Region, From 2022 - 2027 (USD Billion)
  15. China Ophthalmology Therapeutics Market, By Indication, From 2022 - 2027 (USD Billion)
  16. China Ophthalmology Therapeutics Market, By End-User, From 2022 - 2027 (USD Billion)
  17. India Ophthalmology Therapeutics Market, By Indication, From 2022 - 2027 (USD Billion)
  18. India Ophthalmology Therapeutics Market, By End-User, From 2022 - 2027 (USD Billion)
  19. Japan Ophthalmology Therapeutics Market, By Indication, From 2022 - 2027 (USD Billion)
  20. Japan Ophthalmology Therapeutics Market, By End-User, From 2022 - 2027 (USD Billion)
  21. South Korea Ophthalmology Therapeutics Market, By Indication, From 2022 - 2027 (USD Billion)
  22. South Korea Ophthalmology Therapeutics Market, By End-User, From 2022 - 2027 (USD Billion)
  23. Australia Ophthalmology Therapeutics Market, By Indication, From 2022 - 2027 (USD Billion)
  24. Australia Ophthalmology Therapeutics Market, By End-User, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample